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ABSTRACT
The objective of the current proposal is to perform immunotherapy to eradicate prostate cancer and at the same time to avoid the development of autoimmune disease. The proposal contains two tasks. The first task is a combination of TGF-beta insensitive tumor-reactive T cell adoptive therapy for the treatment of mouse prostate cancer. The second task is an inducible TGF-beta based gene therapy.
At the time of this report, we have completed Task 1 and a paper has been published (Cancer Research 65:1761-1769, 2005; Prostate 66: [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] 2005) . Currently, we have modified approaches for studies described in Task 2.
Instead of using the tetracycline-inducible system, we have adapted a herpes simplex thymidine kinase/ganciclovir system, which is working successfully and is in the final phase of completing the task. During the funding period, we have completed studies described in Task 1. Currently, studies described in Task 2 are underway. Briefly, the progress can be summarized in two papers that have been published in Cancer Research 65:1761-1769 and in Prostate 66:235-247. In these papers, we reported the successful eradication of mouse prostate cancer by adoptive transfer of tumor-reactive TGF-beta insensitive CD8+ T cells in tumor bearing mice. In Task 2, we have encountered some technical problem in conducting the tetracycline inducible (Tet-on) system in vivo. We have now changed to using the herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) inducible system, which has been working successfully for us. The project is in its final in vivo phase.
SUBJECT
BODY: Task antibody.
* We have inserted a dominant negative TGF-13 type II receptor (dnTO3RII) expression vector MSC retrovirus gene into the above mentioned tumor reactive CD8+ T cells. Under a separate start site, a green fluorescent protein expressed vector was inserted into the same retrovirus gene. * We have successfully transferred the tumor-reactive TGF-beta insensitive CD8+ T cells to the tumor-bearing male C57BL/6 mice.
* Tumor cells were injected into above recipient mice at 21 days prior to adoptive transfer of CD8+ T cells. At 40 days after the adoptive transfer, animals were sacrificed for inspection of the status of metastasis of TRAMP-C2 mouse prostate cancer cells into the lung. * In mice received na'fve CD8+ T cells, the majority of the tumors were not rejected. In animals received tumor-reactive control CD8+ T cells, there was a partial tumor rejection. However, in animals received adoptive transfer of tumor-reactive TGF-beta insensitive CD8+ T cells, most of the tumors were rejected with no apparent toxicity.
Task 2:
During the course of performing studies described in Task 2, we have encountered technical difficulty in that we were unable to introduce the Tet-on system in our proposed in vivo study. Therefore, we have sought alternative approaches and we have decided to use another inducible system for Taks 2 studies as described below.
In a mammalian cell system, herpes simplex virus thymidine kinase (HSV-tk) can phosphorylate certain nucleotide analogues such as ganciclovir (GCV) that are not metabolized by conventional cellular enzymes. Phosphorylated nucleoside analogues such as GCV triphosphate are potent toxic metabolites for cells. Nevertheless, neither GCV nor HSV-tk alone is harmful to cells. Hence, a conditional cell-depleting effect can be achieved by expressing HSV-tk. Such a HSV-tk/GCV mediated conditional cell-depleting system has been used for the depletion of specially selected cell types by many investigators for more than seventeen years (Minasi et al, 1993; Salomen et al, 1994; Tian et al, 2003; Rettig et al, 2004) . In the present study, we proposed to use this system to conditionally deplete the TGF-P insensitive bone marrow cells.
In collaboration with Dr. Isaac Kim, currently at the Cancer Institute of New Jersey, we have modified the original retroviral vector with TP3RIIDN (Shah et al, 2002a,b) to connect the HSV-tk as the intracellular domain of the TPRIIDN molecule. As such, the viral vector is still function as the dominant negative TfRII. When this viral vector is infected into the target cell, 4 the cell will not only be insensitive to TGF-P3 but will also express thymidine kinase as depicted below. TPRIIDN-tk Construct:
5'LTR I'V I TBRTTDN-tk IRES GEE 3'LTR
Extracellula r Domainr---
The control vector to the above construct is designed by excising the extracellular domain of the TP3RIIDN molecule but retaining the transmembrane domain so that the HSV-tk is still anchored as part of the intracellular domain of the truncated TpRIIDN. When this control vector is infected into the target cell, the cell is unable to bind TGF-f3 but will express thymidine kinase as indicated below. TRANS-tk Construct (Control vector):
Results of our preliminary study using NIH 3T3 cells as the target have demonstrated efficacy of these constructs. The infection rate in NIH-3T3 cells was over 90% and the sensitivity to TGF-13 in these cells is depicted below. When these cells were treated with GCV (10 ug/ml), they rapidly lose the viability and the rate of 3 H-thymidine incorporation. They also have lost the sensitivity to TGF-3, as indicated by a lack of PAI-I luciferase activity when they were treated with TGF-1. In this experiment, we will infect bone marrow cells with the above two types of virus carrying either the TI3RIIDN-tk vector or the TRANS-tk vector. Next, we will perform the in vitro sensitivity toward TGF-P. The TGF-P sensitivity test will include 3 H-thymidine incorporation assay, Smad-2 phosphorylation assay, and PAI-I promoter-reporter assay with and without the presence of TGF-P1 (5 ng/ml), as described earlier (Shah et al, 2002a; Zhang et al, 2005a) . When in vitro tests are completed, we will conduct the in vivo study, the final phase of this task.
RUDN-TK3T3 Viability
KEY RESEARCH ACCOMPLISHMENTS:
*
We have developed an immunotherapy approach in which we perform adoptive transfer of tumor-reactive TGF-beta insensitive CD8+ T cells into tumor bearing mice. These animals were able to reject established mouse prostate tumors metastasized into the lung.
REPORTABLE OUTCOMES:
As a result of this research funded by the Department of Defense, we have published two papers (see appendix).
CONCLUSIONS:
Immunotherapy using adoptive transfer of immune cells is a promising approach for treating cancer patients. The presence of tumor infiltrating lymphocytes (TIL) in the tumor parenchyma has been recognized for three decades 1 . TIL were isolated from surgical specimens, clonally expanded by ex vivo culture, and adoptively transferred to the cancer patients with variable results 2 ' 3. Recently, Yee and coworkers selected antigen specific CD8' T cells for ex vivo expansion and transferred these cells into patients. These CD8÷ T cells did not persist, requiring repeated transfer of CD8÷ T cells in order to elicit responses from the patients 4 . Rosenberg and colleagues treated autologous TIL cells with IL-2 for ex vivo expansion and then transferred them to patients. Again, in order for these cells to "engraft", lymphodepletion was necessary'. These results, although impressive, fall short of our expectation, i.e., total elimination of tumor cells in most patients.
One of the reasons for the failure of TIL in treating cancer is perhaps the fact that the functional role of TIL in cancer has been a subject of controversy 6 . Initially, it appeared that the presence of TIL in the tumor could correlate to prognosis 7 . Subsequent studies showed that TIL were functionally impaired 8-10. This impairment of TIL has been attributed to effects exerted by the tumor microenvironment 11 . When developing an immune-based strategy for cancer therapy, in addition to immune stimulation, the issue of overcoming tumor-derived immune suppression must be taken into consideration 12 . There are 6 potential mechanisms of tumor immune escape: loss of tumor antigen expression; variations in tumor antigen; defects in the transporter associated with antigen presentation; defects in expression of the MHC heavy chain; expression of immunoprotective molecules and release of molecules by tumor cells that disrupt T-cell signaling or induce T-cell death; and upregulation of the expression of immunoprotective molecules (P19, FLIP and the lAP family) that counteract the effects of FASL, granzyme B, CXCL12, FLIP, FLICE, lAP, IL-10, P19, RCAS1 and TGF-P3. Among these molecules, TGF-P3 is an important immunosuppressant 1 3 .
TGF-P has been recognized as a potent immunosuppressive factor 14 1 8 . The high levels of TGF-P produced by cancer cells have a negative effect on surrounding cells, including the host immune cells and have been implicated to play a role in tumor escape from immune surveillance 19,20. Besides the tumor, the immune system, in response to the presence of tumor, is also able to produce a significant amount of TGF-1 to down regulate immune surveillance 21 .
In light of the above discussion, TGF-E] appears to be an attractive target for anti-cancer therapy. Attempts to take advantage of the properties of TGF-P for the treatment of cancer have been reported. Gorelik and Flavell first described the immune-mediated eradication of tumors through the blockade of TGF-P signaling in T cells 17 . These investigators used transgenic mice with TGF-P3 null expression targeted specifically to T cells. Subsequently, our study using transplant of TGF-p-insensitive bone marrow cells also demonstrated a total rejection of metastatic tumor cells 22 ' 23 . However, in both studies, due to the non-specific nature of the immune cells, autoimmune disease eventually developed in the hosts. Results of our recent study have shown that adoptive transfer of tumor-reactive TGF-P-insensitive CD8÷ T cells were able to eradicate established lung metastasis of mouse prostate cancer cells, TRAMP-C2 24 . In the present study, we continue to employ this novel gene therapy approach to investigate the ability these CD8÷ T cells to infiltration into the tumor parenchyma. Here, we report that these 6 CD8÷ T cells show a distinct ability to infiltrate into established tumors, secrete relevant cytokines, and induce apoptosis of tumor cells. (5), authors selected antigen-specific revealed that these CD8+ T cells showed a specific and robust CD8+ T cells for ax viva expansion and transfer into patients.
tumor-killing activity against TRAMP-C2 cells but were ineffective against an irrelevant tumor line, B16-F10. To Responses were remarkable but these CD8* T cells did not persist, deineffecthve a navns anirrelevatumor activity , recip t me w requiring repeated transfer of CD8' T cells to elicit responses from determine the in vivo antitumor activity, recipient mice were the patients. In the second study (6) , authors treated autologous challenged with a single injection of TBAMP-C2 cells for a tumor-infiltrating lymphocyte cells with IL-2 for ex vivo expansion period up to 21 days before adoptive transfer of CD8+ T cells and then transferred to patients following lymphodepletion. was done. Pulmonary metastasis was either eliminated or Although long-term engraftment was achieved, only 4 of 35 significantly reduced in the group receiving adoptive transfer patients showed complete response. These results, although of tumor-reactive TGF-[3-insensitive CD8' T cells. Results of impressive, fall short of our expectation (i.e., total elimination of immunofluorescent studies showed that only tumor-reactive tumor cells in most patients). TGF-3-insensitive CD8+ T cells were able to infiltrate into the In considering tumor immunotherapy, the issue of tumortumor and mediate apoptosis in tumor cells. Furthermore, derived immune suppression must be taken into consideration (1). transferred tumnor-reactive TGF-3-insensitive CD8* T cells It seems that despite the ability to generate immune cells reactive were able to persist in tumor-bearing hosts but declined in against cancer antigens, tumor escape mechanisms can overpower tumor-free animals. These results suggest that adoptive these immune reactions with an eventual tumor progression ( Adoptive therapy using antigen-specific immune cells from vascular endothelial growth factor, IL-10, and transforming growth patients has become an attractive approach for tumor immunofactor (TGF)-15 (9, (12) (13) (14) , also contribute to tumor evasion of the therapy (1). The procedure has been effective in cases of low tumor host immune surveillance. In the present study, we propose to burden. Increased knowledge of immunoregulation and immune focus on TGF-13-mediated evasion of immune surveillance. TGF-P? null expression targeted specifically to T cells. Subsequently, expanded (10S5/mL) in the presence of TRAMP-C2 lysates (1 x 10") and our study using transplant of TGF-1?,-insensitive bone marrow cells irradiated autologous splenoeytes (1 x 10e/ml, at 3,000 Ci) in medium also showed a total rejection of metastatic tumor cells (19, 20) .
containing RPMI 1640 with 10% fetal bovine serum, It-2 (50 units/mL), However, in both studies, due to the nonspecific nature of the anti-CD3' monoclonal antibody (30 ng/mL, R&D Systems), HEPE (25 immune cells, autoimmune disease eventually developed in mmol/L), L-glutamine (4 mmol/L), and 2-ME (25 mmol/L). Media were the hstschanged every 3 days. the hsts.Infection with Retrovirus Containing Dominant Negative TGF-[0 In the present study, we attempted to combine the above two Type 11 Receptor or Green Fluorescent Protein. CD8÷ T cells were advanced technologies by employing adoptive transfer of tumorcultured for at least 10 weeks before they were infected with the murine stem reactive TGF-p?-insensitive CD8÷ T cells into tumor-bearing mice.
cell virus retrovirus containing the dominant-negative TGF-P3 type 11 Here, we report that these CD8' T cells showed a robust antitumor receptor (T[3RIIDN) and green fluorescent protein (GFP; Fig. 2A4 ; refs. 19, activity with little or no apparent toxicity. 20). The infection efficiency was 93.9% for the TI3RIIDN vector and 92.8% for the GFP control vector (Fig. 2B ). There were three types of CD8+ T cells. The first type was tumor-reactive TGF-13-insensitive CD8' T cells (tumor-reactive
Materials and Methods
CD8' T cells infected with the virus containing TP3RIIDN). The second type
Mice and Cells. Male C57BL/6 mice ages 6 to 8 weeks were purchased was tumor-reactive CD8* T cells infected with the virus containing the GFP from The Jackson Laboratory (Bar Harbor, ME) and maintained in control vector. The third type was naive CD8* T cells, which were freshly pathogen-free facilities at the Center for Comparative Medicine at isolated from the spleen of naive donor animals without any treatment.
Northwestern University's Feinberg School of Medicine in accordance with
In vitro CTL Assay. The above three types of CDS* T cells were established guidelines of the Animal Care and Use Committee of subjected to a standard 5S Cr release assay (20) . TRAMP-C2 cells were used Northwestern University. TRAMP-C2 cells obtained from Dr. N. Greenberg as targets. An irrelevant cancer cell line, mouse melanoma cell line, B16-(Fred Hutchinson Cancer Research Center, Seattle, WA) were maintained in F10, was used as a nonspecific control. Target cells were labeled with 0.1 RPMI 1640 (Life Technologies, Rockville, MD) supplemented with 10% heatmCi of SlCr per10Celfo4hurat3Colwdby5assinH-inactivated fetal bovine serum (Life Technologies), 100 units/mL penicillin, media and were seeded in 96-well U-bottomed plates (5,000 cells/well). and 100 jig/mL streptomycin. CDS* T cells were added at different effector/target ratios (1:1 to 100:1) for Generation of Tumor-Reactive CD8* T Cells. Mice were primed with 5 hours. The supernatants were harvested using the Skatron filters (Skatrou irradiated TRAMP-C2 cells (5 x 10s6 per mice at 20,000 Ci) by s.c. injection
Instruments, Sterling, VA) and the released radioactivity was measured every 10 days for a total of three inoculations. Two weeks following the using a gamma counter (LKB Wallac, Turku, Finland). The percent of last vaccination, splenic CD8* T cells were isolated by using murine T cell specific lysis was determined as 100 was excised, fixed in formalin, embedded in paraffin, and serially sectioned was done on either day 3, 7, or 21 following tumor cell injection. Mice were at 4-nm thickness until the block was exhausted. Routine H&E staining was maintained on antibiotics (sulfamethoxazole-trimethoprim) for a minimum done at an interval of every 10 sections. The unstained paraffin sections of 2 weeks to prevent opportunistic infection after the injection. Forty days were used for studies described below. after the adoptive transfer, all animals were sacrificed. Some animals were Nuclear Staining, Apoptosis Assay, and CD8' Staining. Tissue sacrificed sooner than 40 days due to poor health conditions. Serum levels sections were subjected to apoptosis assay by using the TUNEL apoptosis of IFN--y and IL-2 were determined by ELISA. Splenic CD8÷ T cells were kit (Upstate, Lake Placid, NY) and were labeled with Avidin-FITC A. 
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(1** p< 0 . Cancer Research (green, 50 1QL). The same slides were treated with blocking buffer and lysates were prepared by adding radioimmunoprecipitation assay buffer probed for CD8 with rat monoclonal antibody, which was labeled with APC (50 mmol/L Tris-HCI, 1% NP40, 0.25% Na-deoxycholate, 150 mmol/L NaCI, (red; 2 lag/mL, Santa Cruz Biotechnology, Santa Cruz, CA). Finally, the same 1 mmol/L EDTA, 1 mmol/L Na 3 VO 4 , and 1 mmol/L NaF) to cell pellets. slides were stained for cell nuclei with VECTASHIELD mounting media Approximately 30 tog of total protein extract were loaded onto 10% (blue; Vector Laboratories, Burlingame, CA). They were viewed with Nikon TE2000-U fluorescent microscopy (Nikon Co., Tokyo, Japan). Images were digitized by Photoshop 7.0 software.
Expression of TGF-P Receptors in CD8+ T Cells. Normal CD8' T cells,
A.
isolated from freshly harvested spleens, were subjected to fixation and naive GFP TBRIIDN permeabilization in preparation for immunofluorescent staining and flow cytometry analysis. Cells were stained with phycoerytherin-conjugated monoclonal antibody against TGF-1 type I receptor (1:100 dilution; Santa Cruz Biotechnology), and TGF-D3 type II receptor (1:50 dilution, Santa Cruz 3 days Biotechnology). They were then stained with FITC-conjugated monoclonal antibody against CD8 (Santa Cruz Biotechnology). These cells were subjected to dual analysis for phycoerytherin and FITC by flow cytometry.
Western Blot Analysis for SMAD-2 Phosphorylation. CD8+ T cells were treated with or without 10 ng/mL of TGF-[1 for 16 hours (19 10 ng/mL of TGF-I31 for 16 hours. Luciferase activity was assayed by using A medium containing [3H]-thymidine (0.5 pCi/mL; Amersham Biosciences) an assay kit (Promega, San Diego, CA). Activity was normalized based on was introduced and cells were cultured for additional 5 hours. The 13-galactosidase expression with pSVl3-galactosidase. experiment was terminated by washing with warm serum-free medium. Thymidine Incorporation Assay. CD8 T cells (3 X 104 cells per NaOH (0.1 mol/L) was added to all wells (1 mL). An aliquot of 100 jiL was 24 wells) were treated with or without TGF-031 (10 ng/mL) for 16 
Eradication of Autologous Mouse Prostate Cancer
was used for determining the radioactivity. Thymidine incorporation was transfer of tumor-reactive TGF-13-insensitive CD8' T cells had the expressed as the fraction of counts found in controls, least degree of tumor burden (Fig. 4A and B) . There was no TGF-P31 ELISA Assay. TRAMP-C2 cells (1.0 x 107 per T75 flask) were evidence of pulmonary metastasis in the group of mice which cultured in serum-free media for 24 hours. The medium was replaced for received adoptive transfer at 3 days following the injection of 24 hours. The pooled conditioned medium was collected and concentrated tumor cells. One of 10 animals in the 7-day group was found to by using YM-3 Centriprep Centrifugal Filter Devices (Millipore Co., Bedford, have microscopic evidence of pulmonary metastasis at the time of MA). After activation of TGF-[Il by treatment with 1 N HCI (0.1 mL per sacrifice. Two of nine animals in the 21-day group must be 0.5ml, per conditioned media), the mixture was neutralized by 0.1 ml, 1.2 N sacrificed earlier due to poor health conditions and were found to NaOH/0.5 mol/L HEPES. The ELISA assay was carried out using the have pulmonary metastasis of the tumor. Animals which received Quantikine Human TGF-Pl Immunoassay Kit from R&D Systems adoptive transfer of tumor-reactive control CD8' T cells (GFP only) (Minneapolis, MN) . The total number of cells in each flask was counted showed an intermediate degree of tumor burden; whereas those using a Coulter Counter and levels of TGF431 were reported as pg per which received adoptive transfer of naive CD8* T cells were 10 cells per 48 hours.
ineffective in inhibiting tumor progression. Analysis of KaplanFate of Tumor-Reactive CD8' T Cells in the Spleen. Because tumorMeier survival cure showed highly significant differences among reactive CD8' T cells are labeled with GFP, the percent of GFP positive CD8' three treatment groups (Fig. 4C) .
T cells in the spleen was determined by flow cytometry. This experiment Histologic Findings. The most prominent histologic feature of was carried out in both tumor-free animals and in tumor-bearing animals at the tumor tissue in this study is the evidence of inifiltration of CD8* T different time points.
cells into the tumor tissue and the presence of apoptosis in tumor Statistical Methods. All in vitro experiments were done in triplicate, cells of animals which received adoptive transfer of tumor-reactive Numerical data were expressed as mean ± SD. ANOVA and multiple range test were done to determine differences of means among different TGF-f0-insensitive CD8' T cells (the TPRIIDN group; Fig. 6A ).
treatment groups. P < 0.05 was considered statistically significant. The Tumors in animals of the other two groups showed little or no CD8' SPSS 10.0.7 software package (SPSS, Inc., Chicago, IL) was used for T cells and showed no evidence of apoptosis in tumor cells (Fig. 6A) .
analysis. Kaplan-Meier survival curve was analyzed by the log-rank test CD8' T cells, however, are present in the parenchymal tissue of the using the Graphpad Prism 4.02 software (Graphpad Software. Inc., lung in animals of all groups (Fig. 6A) . Although CD8* T cells were San Diego, CA). not observed in tumors of animals in the GFP group, immune cell infiltration was apparent according to histologic observation
Results
( Fig. 5E ), but such immune cell infiltration was more prominent in TGF-I Podutionin RAM-C2 ell. TAMP-2 clls tumor of the T13RIIDN group (Fig. 5F) . No (Fig. 5D ).
TGF-P1 production was measured in other murine cell lines (B316,
Another feature is the lack of infiltration of immune cells in the Renca), human cancer cell lines (LNCaP, PC3, and TSU-Prl) and a air space of the lung in all animals, including those which benign human prostate epithelia] line, RWPE-1 (Fig. 1A) .
received adoptive transfer of tumor-reactive TGF-p-insensitive
Status of TGF-13 Signaling in CD8' T Cells. Under normal CD8' T cells (Fig. 5) . This is in sharp contrast to our earlier conditions, CD8* T cells expressed high levels of type I and type studies, in which recipient animals which received TGF-11 TGF-P receptors (Fig. 1B) and they are highly sensitive to the P,-insensitive bone marrow transplant and developed massive inhibitory effect of TGF-13 (12). When CDS' T cells were infected infiltration of immune cells in the air space of the lung (19, 20). In with the retrovirus containing T13RIIDN, they became insensitive the present study, the air space was devoid of any immune cells, to TGF-P, as shown by following tests. TI3RIIDN infected CD8* T suggesting that autoimmune disease was not apparent in these cells were insensitive to TGF-P1 by a lack of SMAD-2 animals. phosphorylation, which was observed in naive CD8' T cells or Fate of Transferred CD8' T Cells. In the present study, a total cells infected with GFP control vector (Fig. 2C) . Similarly, there of 2 x 106 CD8* T cells were transferred into each recipient animal. was a significant inhibition of plasminogen activator inhibitor-i This number was derived by extrapolating the comparable number promoter-luciferase reporter activity in TGF-Ip-insensitive CD8' T of T cells in adoptive therapy for cancer patients (1, 6). In a similar cells in response to TGF-131 (Fig. 2D) . Finally, these cells were suywt dpietase feprmna eaoamdl insensitive to TG-Imdae niiino hmdn nop-106 antigen-specific T cells were used (21) . To determine the fate of ration assay (Fig. 2E) .thstrnfre celw mesrdhepcnagofGP
In vitro Antitumor Activity of Tumor-Reactive TGFthstrnfre clsw mauedhepcnaeofG -
P-Insensitive CD8* T Cells. Tumor-reactive TGF-p-insensitive positive CD8' T cells in the spleen of recipient animals. When CDS' T cells showed a potent-specific lysis against TRAMP-C2 cells
CD8' T cells were adoptively transferred to tumor-free hosts, there (Fig. 3A) . These cells showed a 5-fold more tumor-killing activity was a linear decay in GFP-positive CD8* T cells reaching 0% by 30 than that of TGF-13-sensitive counterpart and 25-fold over that of days for tumor-reactive CD8' T cells infected with the GFP control naive CD8* T cells. Both the TGF-p-sensitive and TGF-p-insensitive vector and 50 days for tumor-reactive CD8' T cells infected with tumor-reactive CD8' T cells showed a reduced tumor-killing activity the TIRIIDN vector (Fig. 6B) . However, when tumor-reactive TGFwhen incubated with an irrelevant cell line, mouse B16-FIO P-insensitive CD8* T cells were adoptively transferred to tumormelanoma cells (Fig. 3B ).
bearing hosts (the TIPRIIDN group), the percentage of GFP-positive
In vivo Antitumor Activity of Tumor-Reactive TGF-CD8' T cells was maintained at 2% for at least 40 days; whereas in 13-Insensitive CD8' T Cells. In the absence of any intervention, animals which received adoptive transfer of tumor-reactive control at 21 days following the injection of tumor cells, multiple CD8' T cells (the GFP group), GFP-positive CD8* T cells showed a pulmonary gross and microscopic pulmonary metastases were decay curve similar to that in tumor-free hosts with a slight delay evident (data not shown). Those animals which received adoptive (Fig. 6C) (28, 29) . These studies showed a powerful antitumor efficacy. At the same time, the treatment will overcome immunoregulatory role of TGF-p because TGF-V-/-mice had the tumor-derived immunosuppressive effect. excessive inflammatory responses with massive infiltration of A significant part of tumor immunology has focused on the lymphocytes and macrophages in multiple organs. These identification of tumor-specific antigens and the cytolytic T cells syndromes were characterized as autoimmity (17, 29). Results specific for these peptides (22) . Adoptive T-cell therapy using of our past study have shown that mice receiving TGF-[3-antigen-specific CD8' T cells for cancer treatment has been insensitive bone marrow transplants have met with the same attempted with some degree of success (5, 23) and seems to be an fate by developing autoimmune syndrome, although these advantage over the transfer of nonspecific T cells (21) . Results of animals were able to eliminate challenged tumors (19, 20) . In the present study have shown that adoptive transfer of tumorthe present study, the use of the tumor-specific TGF-j3-reactive and TGF-13-insensitive CD8÷ T cells were able to insensitive CD8÷ T cells for the treatment of established cancer specifically target against autologous tumor cells and eradicate did not result in the development of massive infiltration of established pulmonary metastasis. The use of tumor-specific immune cells into the airspace of the lung of tumor-bearing host adoptive immunotherapy has reported before and has clearly and, in tumor-free hosts, these CD8* T cells failed to persist in shown its efficacy by other investigators (23, 24) . The critical issue the host. These preliminary observations seem to suggest an in immunotherapy thus far has been the tumor-derived apparent absence of the development of autoimmune disease in immunosuppressive effect, which remains unresolved, these animals. Further studies are warranted to verify this The mouse prostate cancer model, TRAMP-C2, represents an impression. aggressive line of malignant cells, which secrete large amounts of In summary, the present results showed that adoptive transfer TGF-13. The role of immunosuppressive effect of TGF-13 in cancer of tumor-reactive TGF-p3-insensitive CD8' T cells to tumorprogression has been well established (13, (25) (26) (27) . In the present bearing hosts was able to eradicate autologous tumors. These study, we have shown that, TRAMP-C2 tumors possess potent CD8* T cells have the following characteristic properties. First, immunosuppressive power so that regular CD8' T cells are unable they are specifically reactive against tumor tissues. Second, they to infiltrate into the tumor tissues. However, if these tumorare insensitive to TGF-P3. These two properties endowed these reactive CD8 T cells are engineered and rendered insensitive to CD8* T cells with the ability to infiltrate into tumor tissues and TGF-P3, they are able to infiltrate into the tumor tissue and induce function as potent effectors against tumor cells. Finally, these apoptosis in these established TRAMP-C2 tumors. To the best of cells are able to persist in tumor-bearing hosts but not in our knowledge, studies to test this concept have not been tumor-free hosts. These findings provide a proof of principle that attempted before. These results support the concept that TGF-[P an adoptive transfer of tumor-reactive TGF-13-insensitive CD8+ T isattemp e T portant theget concept thater t . cells may warrant consideration for the treatment of advanced is an important target in cancer therapy.
Results of the present study show that in tumor-bearing hosts, cancers.
the transferred CD8' T cells persist, only if they are tumor reactive and TGF-P3 insensitive. Therefore, adoptive transfer of tumorreactive TGF-p3-insensitive CD8÷ T cells will persist in tumor- INTRODUCTION the presence of tumor, is also able to produce a
Immunotherapy using adoptive transfer of immune significant amount of TGF-P to down-regulate immune cells otherapromising approachi r treatinsr o ancer surveillance [21] . cells is a promising approach for treating cancer TGF-P, therefore, appears to be an attractive target patients. The presence of tumor infiltrating lymphocytes for anti-cancer therapy. Investigators have attempted (TIL) in the tumor parenchyma has been recognized for to utilize the properties of TGF-P advantageously for three decades [1] . TIL were isolated from surgical the treatment of cancer. Gorelik and Flavell [17] first specimens, clonally expanded ex vivo, and adoptively described the immune-mediated eradication of tumors transferred to cancer patients with variable results [2, 3] . through the blockade of TGF-e signaling in T cells.
Recently, Yee and coworkers selected antigen-specific These investigators used transgenic mice with TGF-si CD8+ T cells for ex vivo expansion and transferred these These sinv targeted speic mice w ubsecells into patients. However, these CD8+ T cells did not null expression targeted specifically to T cells. Subsepersist, requiring repeated transfers of CD8+ T cells in quently, our study using transplant of TGF-0-insensiorder to elicit clinical responses [4] . Rosenberg and tive bone marrow cells also demonstrated a total colleagues treated autologous TIL cells with IL-2 for ex rejection of metastatic tumor cells [22, 23] . However, vivolexanuesioeand thenutrangousferrceds wthem to-ten.
autoimmune disease eventually developed in the hosts vivo expansion and then transferred them to patients. in both studies due to the non-specific nature of the Again, in order for these cells to "engraft," lymphodeimmune cells. MoreQ 2 recently, we have shown that pletion was necessary [5] . These results, although adoptive transfer of tumor-reactive TGF-p-insensitive impressive, seem to suggest a missing element in CD8+ T cells, which have high specific tumor killing adoptive transfer of CD8+ T cells for the treatment of ability and were able to eradicate established lung cancerh metastases of mouse prostate cancer cells, TRAMP-C2, The functional role of T in cancer therapy hawhich secreted large amounts of TGF-beta [24] . In the a subject of controversy [6] . Initially, it appeared that the resnce f TL intumrs culdcorrlat to present study, we conducted additional experiments to the presence of TIL in tumors could correlate to delineate the mechanism of the tumoricidal ability of prognosis [7] . Subsequent studies show ed that TIL tu o -e ci e T F0 ns st v C 8 T cls. W tumor-reactive TGF-13-insensitive CD8+ T cells. We were functionally impaired [8-10] from effects exerted report a distinct ability of these CD8+ T cells to infiltrate by the tumor microenvironment [11] . The development into established tumors, secrete relevant cytokines, and of an immune-based strategy for cancer therapy must induce apoptosis of tumor cells. take into account not only immune stimulation, but also the issue of overcoming tumor-derived immune suppression [12] . Among many immunosuppressants, MATERIALS AND METHODS TGF-3 is a potent and important player [13] [14] [15] [16] [17] [18] .
Mice and Cells High levels of TGF-P3 produced by cancer cells have a negative effect on surrounding cells such as the host Male C57BL/6 mice of 6-8 weeks of age were immune cells and have been implicated to play a role in purchased from Jackson Laboratories (Bar Harbor, ME) tumor escape from immune surveillance [19, 20] .
and maintained in pathogen-free facilities at the Center Besides the tumor, the immune system, in response to for Comparative Medicine at Northwestern University h Tumor Reactive,TGF-fP Insensitive CD8÷ T Cells in CancerTherapy 3
Feinberg School of Medicine in accordance with the were tumor reactive CD8+ T cells infected with the established guidelines of the Animal Care and Use GFP-only control vectors. Cells in Group 3 were naive Committee of Northwestern University. TRAMP-C2 is CD8+ T cells. Forty days after CD8+ T cells transfer, an early-passage murine prostate cancer cell line mice were sacrificed by cervical dislocation. Some derived from TRAMP mice that spontaneously develanimals were sacrificed earlier than 40 days due to poor ops prostate cancer due to prostate-specific simian health conditions. The lung from each animal was virus 40 (SV 40) large T tumor antigen (Tag) expression.
isolated for gross and histological examination. At 40 Cells were cultured in RPMI-1640 medium (GIBCO, days, all animals were inspected for the presence of Rockville, MD) supplemented with 10% heat-inactipulmonary metastases. The time of sacrifice for mice in vated fetal bovine serum, 100 U/ml penicillin, and 100 eachgroupwas compared bytheKaplan-Meiermethod. vg/ml streptomycin (GIBCO).
The pulmonary specimens were prepared as serial sections with 4 lim for each through the whole lungs. Generation of Tumor-Reactive TGF-13-insensitive CD8+ T Cells
Immunohistochemistical Staining
Ex vivo expansion of tumor-reactive CD8+ T cells H&E staining: Upon euthanasia, the lung from each from the splenocytes: Male C57BL/6 mice were primed animal was excised, fixed in formalin, embedded in with irradiated TRAMP-C2 cells (5 x 10 6 /mice at paraffin, and serially sectioned at 4 pm thick until the 20,000 ci) by subcutaneous injection every 14 days for embedded tissue was exhausted. Routine Hematoxylin a total of five inoculations. Two weeks following the & Eosin (H&E) staining was performed at an interval of last vaccination, CD8+ T cells from the spleen were every five serial sections. All H&E sections were isolated by using murine T cell CD8 subset column kit evaluated for the presence of tumor tissues by at least (R&D Systems, Minneapolis, MN). CD8+ T cells three independent investigators. PCNA immunologi-(10 5 /ml) were cultured in the presence of TRAMP-C2 cal staining: VECTASTAIN ABC kit (Vector Labs, lysates (1 x 10 6 /ml) and irradiated mouse splenocytes Burlingame, CA) was used according to the procedure (1 x 10 6 /ml at 3,000 ci) in medium containing RPMIfrom the manufacturer with the following adjustment: 1640 with 10% FBS, IL-2 (50 U/ml, R&D), CD3+ monoafter deparaffinization, quenching of endogenous clonal antibody (30 ng/ml, R&D), HEPE (25 mM), peroxidase activity and normal serum pre-blocking, L-glutamine (4 mM), and 2-ME (25 mM) (Sigma, the sections were incubated in diluted mouse monoSt.Louis, MO) at 37°C and under 5% CO 2 . Culture clonal PCNA antibody (1:100, Upstate, Lake Placid, media were changed every 3 days. CD8+ T cells were NY) for 2 hr in room temperature, followed by cultured for around 10 weeks before they were infected incubation with biotinylated goat horse anti-mouse with a retrovirus containing dominant negative TGF-P secondary antibody (1:200, Vector Labs) for 2 hr. Then type II receptor (TPRIIDN-GFP) vector or the control peroxidase substrate solution DAB (DAKO Corpora-GFP only vector. Rendering insensitivity to TGF-P by tion, Carpinteria, CA) was used for desired staining infection with TORIIDN-GFP-containing retrovirus:
and Harris Hematoxylin Solution for counterstaining. Construction of the mouse stem cell retroviral vector (MSCV) containing the dominant negative TGF-P3 type Immunofluorescent co-Staining for Infiltration of II receptor (T3RIIDN) and green fluorescent protein Immune Cells and Secretion of Cytokines (GFP) was performed as previously described [22, 23] .
Unstained paraffin-embedded serial sections of Tumor-reactive CD8+ T cells above were infected with metastatic cancer to the lung were used for immunoretroviral particles containing Tj3RIIDN-GFP or GFP fluorescent staining to detect infiltration of immune only via spin infection as described earlier [22, 23] .
cells (CD8+ T, CD4+ T, B cells, and NK cells) and Infection efficiency was assessed for GFP expression by secretion of cytokines (perforin, Nitric Oxide, IFN-'y, flow cytometry, only the infection efficiency was up to TNF-a, IL-2). The methods of immunofluorescent co-90%, the cells could be used for adoptive transfer that staining were performed by using the assay as was performed 72 hr after infection, previously described [24] . Table I . All the slides microscopic pulmonary metastases were evident. All were depariffinized and blocked by normal serum. The animals were sacrificed 40 days following CD8+ T cells sections were then incubated with the fluorescent transfer, or sooner due to poor health conditions. Mice staining as described before [23] . All the slides were who received tumor-reactive, TGF-0-insensitive CD8+ stained with VECTASHIELD mounting media (blue)
T cells had the least degree of tumor burden. Nine of 12 (Vector lab) for nuclear counterstaining. Staining was animals were free of pulmonary metastasis (Fig. 1A ) viewed with Nikon TE2000-U fluorescent microscopy and 3 mice with metastasis had an average number of (Nikon Corporation, Tokyo, Japan). Images were metastasis per animal (number ± SD) of 1.67 ± 0.5. animal (number ± SD) of 3.7 ± 1.1. Adoptive transfer of naive CD8+ T cells was ineffective in inhibiting tumor Immune-Mediated Tumor Apoptosis Assay progression. All animals in the group had pulmonary Following depariffinizing, tissue sections were submetastasis with the average number of metastasis per jected to apoptosis assay by using the TUNEL animal (number±SD) being 4.8±1.5. Results of jectedtoapoptosis ast(Up staye, bye uding the TKaplan-Meier analysis showed significant survival apoptosis kit (Upstate, Lake Placid, NY) according to differences among the three treatment groups (Fig. 1B) .
the recommendations of the manufacturer. Briefly, the slides were treated with Proteinase K for 30 min at 37°C, incubated with TdT end-labeling cocktail (TdT Buffer, Histological Findings Biotin-dUTP, and TdT, at a ratio of 90:5:5) for 120 min at
The H&E stained sections of tumors that metasta-37'C followed by Avidin-FITC (green) solution (50 l), sized to the lung were evaluated ( Fig. 2A ,C,E with incubated in the dark for 60 min at 37°C. Slides were thenincbate wih 50p1 f bockig bfferat oom magnification of 100 x; 2B, 2D, and 2F with a magnificathen incubated w ith 50 gtl of blocking buffer at room t o f4 0 ) n t m r r m a i as w o r ci e tion of 400x). In tumors from animals who received temperature for 20 min followed by rat monoclonal naive CD8+ T cells, a portion of a large tumor ( Fig. 2A antibody for CD8+ labeled with TR (red) (2 [tg/ml, and 3 mm. in diameter) with marked cytological Santa Cruz) in the dark for 30 min at room temperature. polym m in 2B) withsmated Iytheogical Finally, slides were washed with PBS and stained with polymorphism ( Fig. 2B ) is illustrated. In the mouse meda (lue (ectr lb) or who received adoptive transfer of tumor-reactive VECTASHIELD mounting media (blue)(Vector lab)for control CD8+T cells (GFP only), there is one smaller nuclear staining. They were viewed with Nikon tumor nodule (Fig. 2C, 1 .5 mm in diameter), which TE2000-U fluorescent microscopy (Nikon Corporation, demonstrates some infiltration and degenerative Tokyo, Japan). Images were digitized by Photoshop 7.0 changes of tumor cells (Fig. 2D ). In the tumor from with a PC computer.
mice who received adoptive transfer of tumor-reactive Statistical Analysis TGF-j3-insensitive CD8+ T cells (TP3RIIDN), there is a smaller tumor nodule (Fig. 2E , 0.5 mm in diameter) Analysis of variance and multiple range tests were with heavy lymphocytic infiltrates and marked degenperformed to determine differences of means among erative changes of tumor cells (Fig. 2F) . Another feature different treatment groups. A P-value of less than 0.05 is the lack of infiltration of immune cells in the air was considered statistically significant. SPSS 10.0.7 spaces of the lung in all animals, including those who software package (SPSS Inc.) was used for analysis.
received adoptive transfer of tumor-reactive TGF-0-Kaplan-Meier survival curve was analyzed by the loginsensitive CD8+ T cells, suggesting that autoimmune rank test using the Graphpad Prism 4.02 software disease was not apparent in these animals. This (Graphpad Software Inc., San Diego, CA).
contrasts to our earlier study in which recipient animals who received TGF-0 insensitive bone marrow trans-RESULTS plant developed massive infiltration of immune cells in InVivo Anti-Tumor Activity of Tumor Reactive, the air spaces of the lung [22, 23] . (Fig. 21,J) .
70.
60-
S50-
of apoptosis in tumor tissues (Fig. 3A) . Almost all of On the contrary, the degenerative tumor cells in these infiltrated CD8+ T cells are GFP positive, mice receiving tumor-reactive TGF-0-insensitive suggesting that all these CD8+ T cells were adoptively CD8+ T cells show low proliferative activity (<10% transferred (Fig. 3E) . Also, CD4+, B cells, and NK cells, cells positive for PCNA). (Fig. 2K,L) . There is no thought not abundant, were found in the tumor tissue statistic difference between naive group and GFP (Fig. 3B-D) . Tumors in animals who received adoptive group, but there is a significant difference between transfer of naive CD8+ T cells and tumor-reactive TP3RIIDN groups and the above two groups (P < 0.05).
control CD8+ T cells (Fig. 3A) showed little or no CD8+ T cells. In the latter two groups, CD8+ T cells are present
Infiltration of Tumor-ReactiveTGF-03-insensitive only in the stromal tissues of the lung. Although CD8+ CD8+ T Cells inTumorTissue T cells were not observed in tumors of animals who received tumor-reactive control CD8+ T cells, some
The most prominent histological feature of the lymphocytic infiltration was evident histologically. tumor tissue in this study is evidence of infiltration of However, such lymphocytic infiltration was more Tumor Reactive,TGF-13 Insensitive CD8÷ TCeIIs in CancerTherapy 7 prominent in tumors of the group who received tumornoted in tumors of animals who received naive CD8+ reactive TGF-13-insensitive CD8+ T cells. Very little T cells (Fig. 3A,B,D) , except some B cells (Fig. 3C) (Fig. 3G) . In general, much higher TGF-[3 expression was detected in the tumor parenchyma than .+ .
.. .. peripheral non-tumor tissue in all three groups (Fig. 3F ).
Secretion of Cytokines inTumorTissue
A very high level of perforin ( appeared to have originated from tumor-reactive TGF-",-insensitive CD8+ T cells (Fig. 4E) . Increased levels of IFN-y and IL-2 in tissue corresponded to serum levels ,..
(data now shown). Perforin was not expressed in naive , CD8+ T cells and was expressed very minimally in PCNA tumor-reactive control CD8+ T cells (Fig. 4A) . The ,.Nive .contribution of IFN-y, IL-2, nitric oxide, and TNF-a expression from naive CD8+ T cells and tumor-reactive control CD8+ T cells appears to be negligible (Fig. 4B) . A summary of cytokine expression was described as A prominent feature of TUNEL assay in the tumor an aggressive line of malignant cells, which secrete tissue in this study is the infiltration of CD8 T cells into large amounts of TGF-3. Presently, we have demontisue n hisstuy s te ifitraionofCD8 T els ito strated that TRAMP-C2 tumors, due to their secretion the tumor parenchyma and the presence of apoptosis in strate a t of TGF-2 tu 24r , posse tion tumr cllsof nimls horecive adptie tanser of large amounts of TGF-P1 [24] , possess potent tumor cells of animals who received adoptive transfer immunosuppressive power resulting in the inability of tumor-reactive TGF-3-insensitive CD8+ T cells (the of conventional CD8+ T cells to effectively infiltrate into TPRIIDN group) (Fig. 5) . Tumors in the animals of the the tumor tissue, resulting in a failure of these recipient other two groups showed little or no infiltration of animals to reject tumors. In this study, it is apparent CD8a T cells and demonstrated no evidence of that TGF-p-mediated evasion of the host immune apoptosis. However, CD8l T cells are present in the surveillance system plays a critical role. Once these stromal tissue of the lung in animals of all groups.
tumor-reactive CD8+ T cells were rendered insensitive Meanwhile, there are large amounts of CD8+ T cells to TGF-P, they possessed the ability to eradicate that were induced to undergo apoptosis outside the established pulmonary metastases in a mouse prostate margin of the tumor sites in animals treated with cancer model and to prolong survival in tumor-bearing adoptive transfer of naive CD8+ T cells and tumormice. We observed that adoptive transfer of tumorreactive control Tcreactive TGF-0-insensitive CD8+ T cells can overcome the tumor-derived immune suppressive mechanisms. The most prominent characteristic of these tumor-A significant part of modern tumor immunology has reactive TGF-0-insensitive CD8+ T cells is their ability focused on the identification of tumor-specific antigens to escape the immunosuppressive effect of tumorand the cytolytic T-cells specific for these peptides [25] .
derived TGF-f3 to specifically infiltrate into the tumor When such antigens are defined, therapeutic parenchyma, and to function as potent effectors against approaches use the antigen as the target [26] . However, tumor cells that induce apoptosis in these established any immunotherapeutic approach for cancer necessi-TRAMP-C2 tumors. Our experience has indicated that tates cytotoxic T lymphocytes to enter the tumor a mere acquisition of reactivity against tumor cells in parenchyma. In the past, despite the ability to generate CD8+ T cells was insufficient to achieve tumor immune cells that are reactive against tumor antigens, infiltration by these cells [39, 40] . Therefore, in order evasion of the host immune surveillance by tumor cells for tumor infiltration to occur, these CD8+ T cells must persisted leading to eventual tumor progression be rendered tumor-reactive as well as TGF-p-insensi-[14,27,281. Many possible mechanisms of a tumor's tive. Clinically, the large number of circulating tumor ability to evade host immune surveillance have been antigen-specific CD8+ cytotoxic T lymphocytes in elucidated. These include the down-regulation of individuals with cancer does not correlate with T-cell tumor antigen processing, the inhibitory role of infiltration into cancer tissues or tumor regression CD4+CD25+ T regulatory cells, and the role of tumor- [41, 42] . The inability of immune cells, especially derived immunosuppressive cytokines, which include cytotoxic CD8+ T cell, to infiltrate into the tumor VEGF, IL-10, and TGF-3 [28] [29] [30] [31] [32] . High levels of TGF-0 parenchyma is perhaps, the most important event in produced by tumor cells are able to deter immune cells determining evasion from host immune surveillance from entering the tumor parenchyma [33] [34] [35] [36] [37] [38] . Results by tumor cells. This is because all tumor cells have of the present study seem to indicate that TGF-3 was a acquired the ability to inhibit the host immune system. pulmonary metastasiswere simultaneously stained for cell nucleus (blue),CD8+Tcells (red), and apoptosis (green).Thetumorsitewasidentified by the nuclear staining (blue).CD8+T cells were identified mainly in the lung tissues not in the tumorwith the exception oftheTP3RIIDN group, in which CD8+ T cells (red) were also found within the tumor parenchyma. Frequent tumor apoptotic sites (green) were only found in theToRlIDN group. Although few CD8+ T cells were found undergoing apoptosis (yellow), the majority of the apoptotic cells were derived from the tumor cells (green). (magnification: x 400) Apoptotic activity was evident within the tumor parenchyma of theTPRIIDN group. In contrast, tumors in animalswho received treatments with GFP infected and naoeve CD8+ Tcells did not exhibit tumor cells apoptosis within thetumor parenchyma. Large amounts of CD8+ T cells exhibited apoptotic activity along the peripheryof the tumor parenchyma.
Immunologists have studied properties of tumor cells molecules [43] [44] [45] , cytotoxic T lymphocyte antigen-4 and have recognized many factors that tumor cells have [46], interleukin-13, CD4+CD25+ regulatory employed to inhibit the host immune system. These T cells, and CD4+ natural killer T cells [47] . TGF-P has factors include soluble MHC class I chain-related (MIC) been recognized as one such tumor-derived immune suppressor [171. Results of the present study suggest ACKNOWLEDGMENTS that TGF-0 is a very important tumor-derived immune This study was supported in part by grants from the suppressor. In addition to their ability to infiltrate into Department of Defense (PC970410, PC001491, and the tumor parenchyma, tumor-reactive TGF-j-insensi-PC030038) and the National Cancer Institute tive CD8+ T cells are readily activated [48] , conferring (CA107186). them robust anti-tumor effector function, as indicated by the production of relevant cytokines and widespread apoptosis in tumor cells.
